谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)

Niels W. C. J. van de Donk,Alfred L. Garfall,Lotfi Benboubker,Katarina Uttervall,Kaz Groen,Laura Rosinol,Jeffrey V. Matous,Deeksha Vishwamitra,Caroline Hodin,Tara Stephenson,Keqin Qi,Athena Zuppa,Katherine Chastain,Maria-Victoria Mateos

Clinical Lymphoma Myeloma and Leukemia（2024）

引用 0|浏览4
关键词
MM,tocilizumab,CRS,bispecific antibodies,phase 1/2
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要